Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suzhou Erye Pharmaceutical Co. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly specialized prosecution focus. For a pharmaceutical company, this suggests that their current intellectual property is being evaluated by a single expert group within the USPTO.
The busiest examiner for the company is WARD, PAUL V, who is responsible for 1 pending office action. Since the total number of pending actions is 1, this examiner is the sole individual reviewing the company's active applications. This means the company's immediate success in the Biotechnology & Pharmaceuticals field depends on the specific feedback of WARD, PAUL V. Practitioners should focus their efforts on this 1 distinct examiner, as no other art units are currently influencing the portfolio's trajectory.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021832 | SALT FORM AND CRYSTAL FORM THEREOF OF SULFONYLUREA RING SUBSTITUTED COMPOUND | WARD, PAUL V | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18021832 | SALT FORM AND CRYSTAL FORM THEREOF OF SULFONYLUREA RING SUBSTITUTED COMPOUND | WARD, PAUL V | 1622 | §102 | Final Rejection | — | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Erye Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul V Ward has the most, with 1 of Suzhou Erye Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
